A Study of Acne Treatment in Children Ages 9 to 11
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00907335 |
Recruitment Status :
Completed
First Posted : May 22, 2009
Results First Posted : March 11, 2011
Last Update Posted : February 15, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acne Vulgaris | Drug: Retin-A Micro 0.04% facial acne treatment Drug: Vehicle control | Phase 2 |
Approximately 100 female and male subjects, aged from 9 to 11 years of age, will be enrolled in this randomized, double blind, multi-center study.
Following satisfaction of entry criteria and screening procedures, subjects will receive either RETIN-A MICRO 0.04% or a color matched gel vehicle for once daily use during the 12-week treatment period. Subjects will be monitored for safety throughout the study and for signs and symptoms of local irritation at baseline, and at weeks 2, 4, 6, 8, 10 and again at study completion, week 12.
Efficacy will be assessed by facial lesion counts and by utilizing scales for Investigator's Global Evaluation of Acne Severity (IGA #1 and IGA #2) and Investigator's Global Assessment of Improvement (IGA #3). All efficacy parameters with the exception of IGA #3 will be measured at baseline and weeks 2, 4, 6, 8, 10 and 12. The Investigator's Global Assessment of Improvement (IGA #3) will be done at Week 12 only. At selected sites, photographs will be taken at Baseline and weeks 2, 4, 8 and 12.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 110 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multi-Center, Double Blind, Vehicle Controlled, Study of Retin-A Micro 0.04% in the Treatment of Pediatric Acne Vulgaris in Children, Ages 9 to 11 Years of Age |
Study Start Date : | February 2009 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | December 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: Retin-A Micro
Retin-A Micro 0.04% facial acne treatment used once daily
|
Drug: Retin-A Micro 0.04% facial acne treatment
Retin-A Micro 0.04% facial acne treatment used once daily
Other Name: facial acne treatment |
Placebo Comparator: Vehicle Control
Color matched facial gel vehicle control used once daily
|
Drug: Vehicle control
Color-matched facial gel vehicle control used once daily
Other Name: placebo |
- Change From Baseline in Total Non-inflammatory Lesion Count [ Time Frame: Baseline to Week 12 ]Change from Baseline to Week 12 (Week 12 minus Baseline) in the total non-inflammatory acne lesion count. Facial acne lesion counts consisted of non-inflammatory lesions and inflammatory lesions. The total non-inflammatory acne lesion count is the sum of open and closed comedones, change from Baseline was calculated as the value after Baseline minus the baseline value, and negative changes indicated lesion improvement.
- Change From Baseline in Lesion Counts [ Time Frame: Baseline to Week 12 ]Change from baseline in Lesion Count by the following categories: Facial acne lesion counts consisted of non-inflammatory lesions and inflammatory lesions. Inflammatory lesions were the sum of papules and pustules. Total lesions were the sum of non-inflammatory and inflammatory lesions, plus nodules/cysts. For each lesion type, change from Baseline was calculated as the value after Baseline minus the baseline value, and negative changes indicated lesion improvement.
- Measurement of Success 1 [ Time Frame: Week 12 ]Participants achieving success according to the Investigator Global Assessment (IGA #1) - (Pediatric Acne Scale) has ordinal response categories identified as clear (0), almost clear (1), mild (2), moderate (3), severe (4), and very severe (5). The number of participants for which treatment was considered successful was based on 2 criteria: 1) improvement by at least 2 grades from the baseline score, and 2) ratings of clear or almost clear.
- Measurement of Success 2 [ Time Frame: Week 12 ]Participants achieving success according to dichotomized Investigator Global Assessment (IGA) scores - Food and Drug Administration Score (IGA#2) The IGA #2 (static 5 point scale recommended in the FDA acne guidelines) has ordinal response categories identified as clear (0), almost clear (1), mild (2), moderate (3), and severe (4). The number of participants for which treatment was considered successful was based on 2 criteria: 1) improvement by at least 2 grades from the baseline score, and 2) ratings of clear or almost clear.
- Measurement of Success 3 [ Time Frame: Week 12 ]Participants achieving success according to Investigator Global Assessment (IGA#3) scores. At Week 12, the IGA #3 rated the subject's improvement over Baseline by using the following categories: Excellent, Good, Fair, No Change, Worse. The number of participants for which treatment was considered successful was based on the IGA #3 success criteria defined as achievement of "Excellent" or "Good" scores.
- Global Assessment [ Time Frame: Baseline to Week 12 ]Participants showing improvement from baseline in the Investigator's Global Assessment, in the Intent to Treat population using the Last Available Measurement and imputation technique of Last Observation Carried Forward, rating the subject's improvement over Baseline by using the following categories: Excellent, Good, Fair, No Change, Worse.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 9 Years to 11 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and non-pregnant, non-nursing females, 9 to 11 years, with facial pediatric acne vulgaris
- Minimum of 20 non-inflammatory lesions (open and closed comedones)
- Minimum of 30 total facial lesions (sum of inflammatory and non-inflammatory)
- Must have at least a rating of grade 3 on the Investigator Global Assessment Scale for acne severity (IGA #1) at baseline
Exclusion Criteria:
- Known sensitivity to any of the ingredients in the study medication;
- Any nodulocystic acne lesions
- Use of acne devices or systemic therapy with antibiotics within two months prior to start and throughout the duration of the study
- Use of systemic therapy with retinoids within four months prior to study start and throughout the duration of the study
- Topical use of topical retinoids within two weeks prior to study start and throughout the duration of the study
- Topical use of antibiotics, steroids and/or other non-retinoid topical acne products within two weeks prior to study start and throughout the duration of the study
- Use of an experimental drug or device within 60 days prior to study start;
- Use of hormonal therapy within 3 months prior to study start
- History of evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication
- Any significant medical conditions that could confound the interpretation of the study
- History of/or current facial skin cancer
- Inability to refrain from use of all facial products other than those supplied by the study, while participating in the study
- No use of tanning booths, sun lamps, etc.
- Subject is a family member of the employee or the investigator

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00907335
United States, California | |
Encino Research Center | |
Encino, California, United States, 91436 | |
Children's Hospital and Health Center | |
San Diego, California, United States, 92123 | |
United States, Florida | |
Department of Dermatology, University of Miami | |
Miami, Florida, United States, 33136 | |
United States, Illinois | |
Department of Dermatology, Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, Kentucky | |
Dermatology Associates | |
Louisville, Kentucky, United States, 40202 | |
United States, New Jersey | |
UMDNJ-RWJ Medical School | |
Somerset, New Jersey, United States, 08873 | |
United States, New York | |
SUNY Downstate Medical Center Department of Dermatology | |
Brooklyn, New York, United States, 11203 | |
United States, Ohio | |
Dermatology Research Associates | |
Cincinnatti, Ohio, United States, 45230 | |
United States, Pennsylvania | |
Skin Study Center | |
Broomall, Pennsylvania, United States, 19008 | |
Yardley Dermatology Associates | |
Yardley, Pennsylvania, United States, 19067 | |
United States, Rhode Island | |
Omega Medical Research | |
Warwick, Rhode Island, United States, 02886 | |
United States, Texas | |
University of Texas Medical School at Houston | |
Houston, Texas, United States, 77030 |
Study Director: | Ana Rossi, MD | Johnson & Johnson Consumer and Personal Products Worldwide |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Valeant Pharmaceuticals International, Inc. |
ClinicalTrials.gov Identifier: | NCT00907335 History of Changes |
Other Study ID Numbers: |
CA-P-6397 |
First Posted: | May 22, 2009 Key Record Dates |
Results First Posted: | March 11, 2011 |
Last Update Posted: | February 15, 2012 |
Last Verified: | February 2012 |
Keywords provided by Valeant Pharmaceuticals International, Inc.:
acne irritation objective sensory methods |
Additional relevant MeSH terms:
Acne Vulgaris Acneiform Eruptions Skin Diseases Sebaceous Gland Diseases Benzoyl Peroxide |
Tretinoin Dermatologic Agents Antineoplastic Agents Keratolytic Agents |